

Name	Ingo Ringshausen
Title	Professor Dr. med.
Email	ir279@cam.ac.uk
Current position	1. Principal Investigator Wellcome Trust/ MRC Cambridge Stem Cell Institute, Department of Haematology University of Cambridge 2. Consultant Haematologist, Addenbrooke's University Hospital Cambridge
Research interests	Signaling and microenvironment in lymphoid diseases

Medical Training/ Licenses/ Qualifications

1992– 1999	Medical School, Johannes Gutenberg-University, Mainz, Germany
1998	University of Western Ontario, London, Ontario, Canada
1999	Preliminary German License as Physician (AIP)
2000	Full German License as Physician
1999 – 2003	Postgraduate Medical training as Resident Technical University Munich
2008	Assistant Professor, Internal Medicine, Technical University Munich
2006 – 2009	Postgraduate Medical training as Fellow Technical University Munich
2009	Board Certification in Internal Medicine
2010	Consultant for Haematology/ Oncology at the University Hospital, Technical University Munich, Germany
2010	Board Certification in Haematology and Medical Oncology
Since 2013	GMC registered in Internal (General) Medicine
Since 2014	Honorary Consultant/ Cambridge University Hospital
Since 2015	GMC registered in Haematology
Since 2017	Extraordinary Professor of Medicine, Technical University, Munich

Occupational history

1999-2003	House Officer & SHO, 3 rd Medical Department, Klinikum rechts der Isar, Technical University Munich, Germany.
2003-2006	Research Fellow, University of California, San Francisco (UCSF), U.S.A.
2006-2013	Registrar/ Consultant Haematologist, 3 rd Medical Department, Klinikum rechts der Isar, Technical University, Munich, Germany.
Since 2014	Principal Investigator/ Consultant Haematologist, Cambridge University & Addenbrooke's hospital, Cambridge, UK.

Scientific training/ career/ employment

1994–1997	Doctoral thesis " <i>Induction of common γ-chain by Interleukin-1 and Interleukin-4 in non-hematopoietic cells</i> ", Supervisor: Professor Christian Peschel, Department of Haematology/ Oncology Johannes Gutenberg-University Mainz, Germany
2000	Defense of Dissertation, " <i>magna cum laude</i> "
2003 – 2006	Research fellow Comprehensive Cancer Center University of California, San Francisco (UCSF), U.S.A. Laboratory of Professor Gerard I. Evan PhD
2009 – 2013	Principal Investigator, Department of Haematology/Oncology, Technical University Munich (<i>on a 20% Research/ 80% Clinical Service contract</i>)

- Since 2014 Principal Investigator, Department of Haematology,
CRUK Senior Fellow, University of Cambridge, UK
- Since 2016 Principal Investigator Cambridge Stem Cell Institute (CSCI)

Academic leadership roles

- Founder and Organizer of the Annual International UK-Germany Lymphoma Retreat (Inaugural meeting 2015)
- Founder and Organizer of the Cambridge International Symposium on Lymphoma Biology (Inaugural meeting July 2018)
- Founder and Co-organizer of the Cambridge Lymphoma Network (CaLy)

Clinical leadership roles

- Co-chair of the CLL/lymphoma service at Addenbrooke's University hospital
- Board member of the UK-CLL forum (since 2015)
- Principal Investigator on several phase II/III clinical trials

Awards/ Prizes:

- 2002 Postdoctoral Fellowship award Deutsche Krebshilfe (German Cancer Aid)
- 2013 Cancer Research UK (CRUK) Senior fellowship
- 2019 Terry Hamblin Price from the UK-CLL society
- 2020 Terry Hamblin Price from the UK-CLL society

Scientific contributions

My scientific interest lies in understanding intrinsically and extrinsically altered signaling pathways in chronic lymphocytic leukaemia (CLL) and B cell malignancies and how they contribute to disease progression and drug resistance. Through my work, PI-3 kinase was identified as a drug target in CLL (Blood 2002), providing a scientific foundation for the development and use of PI-3K inhibitor in this disease. Nowadays, my research focuses on understanding bi-directional dependencies between malignant B cells and cells of the microenvironment. We identified PKC-activation in the tumour microenvironment as a novel and crucial factor contributing to drug resistance in B cell malignancies. Our discoveries have led to a patent application for the use of PKC-inhibitors as chemosensitiser, a clinical trial (MaVeRiC-trial) and a spin out company (Stroma Biosciences) in 2020, focusing on the identification and targeting of tumour-stroma cells in B cell malignancies.

Selected Publications (Peer reviewed)

(A complete list can be found on <https://www.ncbi.nlm.nih.gov/pubmed/?term=ringshausen+i>)

1. Mangolini M., Maiques-Diaz A., Charalampopoulou S., Gerhard-Hartmann E., Bloehdorn J., Moore A., Lu J., Roamio Franklin VN., Chilamakuri C., Moutsopoulos I., Rosenwald A., Stilgenbauer S., Zenz T., Mohorianu I., D'Santos C., Deaglio S., Martin-Subero IJ., **Ringshausen I.**: *Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape*. Nat Commun. 2022 Oct 20;13(1):6220
2. Chen J., Sathiaseelan V., Moore AD., Tan S., Chilamakuri C., Franklin VN., Shahsavari A., Jakwerth C., Hake SB., Warren A., Mohorianu I., D'Santos C., **Ringshausen I.** *ZAP-70 constitutively regulates gene expression and protein synthesis in chronic lymphocytic leukemia*. Blood 2021 Feb 22; blood.2020009960
3. Santoro A, Andrei C, Bryant C, Calderbank E, Wray A, Baxter JE, Godfrey A, Laurenti E, **Ringshausen I.** *Chronic lymphocytic leukemia increases the pool of peripheral blood hematopoietic*

stem cells and skews differentiation. Blood advances 2020 Dec 22;4(24):6310-6314

4. Park E., Chen J., Moore A., Mangolini M., Santoro A., Boyd JR., Schjerven H., Ecker V., Buchner M., Williamson JC., Lehner P., Gasparoli L., Williams O., Blöhdorn J., Stilgenbauer S., Leitges M., Egle A, Schmidt-Supprian M., Fietze, S., **Ringshausen I.** *Stroma cell Protein kinase C-β inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance.* Sci. Transl. Medicine 12,eaax9340 (2020)
5. Mangolini M, Götte F, Moore A, Ammon T, Oelsner M, Lutzny-Geier G, Klein-Hitpass L, Williamson JC, Lehner PJ, Dürig J, Möllmann M, Rásó-Barnett L, Hughes K, Santoro A, Méndez-Ferrer S, Oostendorp RAJ, Zimmer-Strobl U, Peschel C, Hodson DJ, Schmidt-Supprian M, **Ringshausen I.** *Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia.* Nat Commun. 2018 Sep 21;9(1):3839
6. Wagner M, Oelsner M, Moore A, Götte F, Kuhn PH, Haferlach T, Fiegl M, Bogner C, Baxter EJ, Peschel C, Follows GA, **Ringshausen I.** *Integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia.* Blood. 2016 Jan 28;127(4):436-48
7. Lutzny G., Kocher T., Rudelius M., Schmidt-Supprian M., Klein-Hitpass L., Finch A., Dürig J., Haferlach T., Seifert M., Wanninger S., Oostendorp R., Ruland J., Leitges M., Kuhnt T., Wagner M., Feuerstacke Y., Peschel C., Egle A. and **Ringshausen I.:** *Protein kinase C-β dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B-cells in vivo.* Cancer Cell. 2013 Jan 14;23(1):77-92.
8. **Ringshausen, I.,** C.C. O'Shea, A.J. Finch, L.B. Swigart, and G.I. Evan: *Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo.* Cancer Cell, 2006. 10(6): p. 501-14.
9. Christophorou, M.A., **I. Ringshausen,** A.J. Finch, L.B. Swigart, and G.I. Evan: *The pathological response to DNA damage does not contribute to p53-mediated tumour suppression.* Nature, 2006. 443(7108): p. 214-7.
10. **Ringshausen, I.,** F. Schneller, C. Bogner, S. Hipp, J. Duyster, C. Peschel, and T. Decker: *Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta.* Blood, 2002.